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Summary Non-thyroid neoplasis were analysed by Southern blot of genomic DNA and DNA prepared by
reverse transcription and amplification by polymerase chain reaction (RT/PCR) for the activation of the RET
oncogene. It is known that the rearrangement of RET occurs in about 10%-20% of human thyroid papillary
carcinomas. None of 528 non-thyroid tumours showed rearrangement of the RET proto-oncogene, whereas
three out of 30 thyroid papillary carcinomas were positive for RET activation. Therefore the activation of
RET seems to be a somatic cell mutation specific to human thyroid carcinomas.
The frequent activation of the RET proto-oncogene has been
recently demonstrated in human thyroid carcinomas of the
papillary histotype and in the TPC-1 human papillary
thyroid carcinoma cell line (Fusco et al., 1987a; Grieco et al.,
1990; Bongarzone et al., 1989; Ishizaka et al., 1990; Jhiang et
al., 1992). The RET proto-oncogene encodes for receptor-
type tyrosine-kinase proteins (Takahashi & Cooper, 1987;
Takahashi et al., 1988; Tahira et al., 1990). The activation of
RET in thyroid carcinomas consists of the truncation of its
N-terminal region and fusion of the tyrosine-kinase domain
and the 5'-terminal region of a still uncharacterised gene
named H4 or DlOS170. We have denominated RET/PTC
(also named retTPC) the resulting chimeric oncogene (Grieco
et al., 1990; Ishizaka et al., 1990).
This chimeric gene generates chimeric mRNA transcripts
encoding two types of fusion proteins of about 57 Kd, the
C-termini of which are different due to alternative splicing,
whereas the molecular weights of the RET proto-oncogene
products are 140 and 170 kDa (Takahashi et al., 1991;
Ishizaka et al., 1992; Lanzi et al., 1992). The RET/PTC
product localises in a soluble cytoplasmic fraction and is
constitutively phosphorylated, whereas the RET proto-
oncogene products localise in a membrane fraction and are
not phosphorylated (Ishizaka et al., 1992; Lanzi et al., 1992).
More recently we have reported that in some cases the fusion
of the tyrosine-kinase domain of activated RET occurs with
genes other than H4 (Santoro et al., 1992; Lanzi et al., 1992).
We have also demonstrated that both the H4 and RET genes
are located on the long arm of chromosome 10 and that a
chromosomal inversion is responsible for their fusion
(Pierotti et al., 1992).
By analysing human thyroid carcinomas by Southern blot,
it has been demonstrated that the activation of RET is
restricted to carcinomas of the papillary histotype and that
this activation is quite frequent (10-30%), with significant
differences between different countries, with studies being
performed in Italy, France, Japan and the United States
(Santoro et al., 1992; Jhiang et al., 1992; Wajjwalku et al.,
1992). However, in another study, RET/PTC activation has
been detected in four out of 19 follicular adenomas and 1 out
of two adenomatous goiters (Ishizaka et al., 1991).
The activation of RET/PTC may be detected by Southern
blot analysis of genomic DNA or of the products of reverse
transcription polymerase chain reaction (RT-PCR), the
second being a very sensitive method which can detect the
RET/PTC transcripts in RNA sample extracted from a cell
mixture of a single transcript-positive cell and 105 transcript
negative cells (Ishizaka et al., 1991).
Although the involvement of RET was studied extensively
in thyroid carcinomas, there is no report describing the
involvement of this oncogene in various human tumours
other than the thyroid. To investigate the possibility that
RET activation might be involved in neoplasias other than
papillary thyroid carcinomas, we have analysed 528 non-
thyroid human tumour samples originating from several tis-
sues including carcinomas, sarcomas, hematopoietic and
neuroepithelial neoplasias.
No RET activation has been detected in non-thyroid
tumours; whereas we have detected RET activation in three
out of 30 papillary thyroid carcinomas.
Materials and methods
DNA extraction and Southern blot analysis
The tumour samples were frozen in liquid nitrogen and
stored frozen until DNA extractions were performed.
Thyroid tumours were obtained from the Laboratoire d'His-
tologie et de Cytologie, Centre Hospitalier Lyon Sud,
France. High molecular weight DNA extraction from
tumours and Southern blot analyses were performed accord-
ing to standard procedures (Sambrook et al., 1989). Briefly,
10 micrograms of DNA were digested with restriction
enzymes (Amersham Corp., Promega Biotec.), electro-
phoresed through 0.8% agarose, transferred to Nylon filters
(Hybond-N, Amersham Corp.) and hybridised to 32P-labelled
probes by the random oligonucleotide primer kit (Amersham
Corp.). Hybridisations and washings were carried out under
stringent conditions as previously described (Grieco et al.,
1990). Autoradiography was performed by using Kodak
XAR films at 70°C for 1-7 days with intensifying screens.
Extraction oftotal RNA and DNA synthesis by RT-PCR
Total RNA was extracted by the reported method (Chom-
cziynski & Sacchi, 1987). Each tumour was minced in a
microcentrifuge tube with a disposable pestle in a guan-
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idinium solution. To avoid contamination pipette tips with
filter plugs (USA/Scientific plastics, FL) were used through-
out all the experiments; cDNA was synthesised as described.
Briefly, 1 fig total RNA was denatured for 10 min at 68°C,
then incubated with 200 units of reverse transcriptase (BRL)
of Moloney Leukaemia Virus in a total of 20 microliters
reaction mixture for 30 min at 37°C in the presence of 1 mM
of each deoxynucleotide (Pharmacia) and 100 pmoles of ran-
dom hexamers (Pharmacia). The cDNA was amplified by
PCR by the method described by E.S.Kawasaki (Kawasaki et
al., 1990). The primers used for PCR amplification of the
cDNAs of the RET/PTC and c-raf-1 transcripts, summarised
in Table I, were synthesised by a DNA synthesiser (Applied
Biosystem). The forward primer for RET/PTC was syn-
thesised according to the 5' replaced sequences and the
reverse primer was synthesised according to the RET proto-
oncogene sequence. The cDNA of c-raf-1 was amplified for
evaluating the quality of each RNA sample. Primers were
designed so as to amplify cDNA encompassing through
exons 4-9 of the c-raf-1 gene. Expected sizes of amplified
DNAs were 96 base pairs (bp) for RET/PTC and 557 bp for
c-raf-I (Bonner et al., 1986). Each 1 microliter of the cDNA
reaction mixture was incubated with Taq polymerase
(Takara) in the presence of 100 pmoles of both forward and
reverse primers. Thirty-five cycles of PCR were performed
with a thermal cycler (Perkin-Elmer-Cetus) under the condi-
tions of 94°C for 30 s, 55°C for 1 min and 72°C for 2 min.
The RET/PTC and c-raf-1 cDNAs were amplified in the
same reaction mixture. After PCR, each reaction was loaded
onto an agarose gel. The DNAs were transferred to nylon
filters and hybridised. For detecting the RET/PTC transcripts
we used as a probe a 31 mer oligonucleotide designed to
recognise the chimeric point and for c-raf-1 transcripts, a
27 mer oligonucleotide synthesised according to the sequence
of exon 8 of c-raf- (Table I).
For the three cases positive for activation of RET found
by genomic Southern blot analysis, PCR was performed
according to the already published procedure (Santoro et al.,
1992).
Results
Southern blot analysis ofgenomic DNA
We have demonstrated that the RET/PTC oncogene (also
named retTPC) derives from the truncation of the NH2-
terminal region of the RET proto-oncogene and fusion of its
C-terminal region to a still uncharacterised gene, named H4
or DlOS170. In some cases the fusion does not occur with
H4 but with different genes (Santoro et al., 1992). In every
case the breakpoint of the RET gene occurs in an intronic
sequence that resides between its tyrosine-kinase and trans-
membrane encoding domains. This rearrangement can be
detected by Southern blot analysis of the tumour DNA
(Grieco et al., 1990; Jhiang et al., 1992). A schematic
representation of the genomic restriction map of the RET
proto-oncogene and the probes that we have used is shown
in Figure 1.
We have analysed 458 neoplastic samples, 40 thyroid and
418 non-thyroid, for RET activation by probing Southern
blots with a 1 Kbp BglII-BamH1 RET specific DNA frag-
ment. This fragment is able to detect the region within the
RET gene where the rearrangement can occur (Probe 1 of
Figure 1). This probe detects a 6.3 Kbp fragment after
restriction with EcoRl, a 3.7 Kbp BamHl and a 9.3 Kbp
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Figure 1 Schematic representation of the genomic restriction
map of the RET proto-oncogene. The approximate positions of
the coding sequences for the transmembrane (TM) and tyrosine
kinase (TK) domains are shown. Below the map are illustrated
the DNA probes used in this study. The restriction sites shown
are E: EcoRl; B: BamHl; Bg: BglII.
HindIII fragments in normal human DNA (Santoro et al.,
1992). None of the 418 non-thyroid neoplastic tissues
(oesophageal, stomach, colon, liver, lung, kidney, ovarian,
breast and prostate carcinomas; fibro and osteosarcomas,
leukaemia and lymphomas, pituitary and parathyroid
adenomas, neuroblastomas, gliomas, pheocromocytomas,
and insulinomas) showed any rearrangement of the RET
oncogene (Table II). None of the ten non-papillary thyroid
carcinomas scored positive. Conversely we have found that
three out of 30 thyroid papillary carcinomas, collected in
France, showed additional rearranged bands and this result
was demonstrable with at least three different restriction
enzymes (Figure 2, lanes 1, 7, 8, 9, 10, 11, and 12).
In order to further characterise this rearrangement we have
also analysed these positive samples with a NH2-terminal
proto-RET specific sequence (1.8 kbp BamH1 DNA frag-
ment; probe 2 of Figure 1). Two out of these three positive
samples showed rearranged bands also when probed with
probe 2 (data not shown). This result indicated that the RET
Table II Tumours scored negative for PTC activation by Southern
blot analysis
Tumour Genomic DNA RT-PCR
Lung carcinomaa 35 22
Gastric carcinoma 45 23
Breast carcinoma 40 13
Colon carcinoma 37 2
Ovarian carcinoma 12
Uterine carcinoma 10 13
Renal carcinoma 10 10
Hepatocellular carcinoma 3 16
Esophageal carcinoma 45
Gall bladder carcinoma - I
Choledocal carcinoma - I
Prostate carcinoma - 5












a25 of these lung carcinomas were small cell lung cancers.
Table I Primers for PCR amplification and probes used for Southern blotting
RET/PTC c-raf-1
Forward primer 5'-ACTGAAGTGCAAGGCACT-3' 5'-GATTTCCTGGATCATGTT-3'
Reverse primer 5'-AAGTTCTTCCGAGGGAATTC-3' 5'-GCTGGCACGGGGGTTTTC-3'
Probes for Southern 5'-CCAGCGTGACCATCGAG 5'-CTGATTCGCTGTGACTTCGAA
GATCCAAAGTGGGA-3' TTGCAT-3'
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Figure 2 Activation of the RET oncogene in papillary thyroid carcinomas. Southern blot analysis of DNA extracted from three
different neoplastic specimens (Panels a, b, and c respectively). Ten ug of DNA were digested with EcoRl, BamHl or HindII
restriction enzymes (Amersham Corp.), transferred to Nylon filters (Hybond N, Amersham Corp.) and hybridised to a 1.0 Kbp.
BamHl-BglII RET specific DNA probe (showed in Figure 1). (a) Lane 1: DNA from papillary carcinoma number 1 digested with
EcoRl; Lanes 2 and 3: normal human DNA digested with EcoRl. (b) Lanes 4, 5 and 6: normal human DNA digested with EcoRl,
BamHl and HindlII respectively; Lanes 7, 8 and 9: DNA from the papillary carcinoma number 2 digested respectively with EcoRl,
BamHl and HindIII. (c) Lanes 10, 11 and 12: DNA from the papillary carcinoma number 3 digested with EcoRl, HindIII and
BamHl respectively. The arrows indicate the size of the normal fragments.
sequence located upstream of the breakpoint was not deleted
in these two cases. Since both the RET proto-oncogene and
H4 map to the long arm of chromosome 10, we hypothesise
the possibility that a chromosomal inversion could lead to
the H4/RET fusion. In fact we have reported that an inver-
sion (10) (qll.2-21.1) caused the H4/RET fusion in at least
four cases of papillary thyroid carcinoma (Pierotti et al.,
1992). Moreover the three positive thyroid samples were
analysed by RT-PCR as described before (Santoro et al.,
1992). Two of them showed amplification of a fragment of
the expected size of 363 bp, confirming that in these cases
the activation of RET was due to an H4/RET fusion (data
not shown). In the other positive thyroid papillary carcin-
oma the activation of RET, demonstrated by Southern
analysis, was probably due to its fusion to a gene different
from H4.
Analysis of the RET/PTC transcripts
To study the activation of the RET proto-oncogene in
human tumours, we have also used the more sensitive RT-
PCR-Southern blotting technique to analyse 110 non-thyroid
human tumours. The results was that all tumours listed in
Table II, carcinomas of lung, stomach, breast, colon, uterus,
kidney, liver, pancreas, prostate, choledochal and gallblad-
der, and lymphomas, were negative for the RET/PTC tran-
script. Representative results are shown in Figure 3. RNA
extracted from the RET/PTC-positive TPC-1 cell line was
used as a positive control. From TPC-1 RNA a fragment of
about 100 bp in length was amplified which hybridised to a
PTC chimeric point detecting probe (Figure 3a and b, lane
15) whereas in Figure 3 we show that 14 samples of breast
carcinomas and 14 hepatocellular carcinomas gave no signal
for the RET/PTC trancript (Figure 3a and b, lanes 1-14).
To exclude the possibility that cDNAs were not amplified
because of RNA degradation in these samples, c-raf-l cDNA
was amplified in the same reaction tube in which the RET/
PTC cDNA was amplified and probed to a c-raf-1 specific
oligonucleotide. A cDNA fragment of the expected size
(about 500 bp) was amplified from all samples except for two
samples of breast carcinoma (Figure 3a, lanes 8 and 9). These
two samples were omitted for evaluating the involvement of
RET/PTC.
Discussion
The RET transforming gene has been found activated in vivo
only in papillary thyroid carcinoma (Fusco et al., 1987a;
Grieco et al.,1990; Santoro et al., 1992; Jhiang et al.,1992;
Wajwalku et al., 1992), in a papillary thyroid carcinoma cell
line (Ishizaka et al., 1990), in four follicular thyroid
adenomas and in one adenomatous goiter (Ishizaka et al.,
1991). No RET activation has been described in non-thyroid
tumours apart from some cases in which RET rearrange-
ments occurred during the transfection procedure (Takahashi
et al., 1985; Koda, 1988; Ishizaka et al., 1989).
In this paper we confirm the frequency of about 10% of
RET rearrangement in thyroid tumours from France, as
previously described (Santoro et al., 1992) and we report that
no RET activation can be detected in 528 neoplasias of
non-thyroid origin either by Southern blot analysis or by the
much more sensitive PCR technique. However it is note-
worthy that with an average frequency of RET-activation of
10%, the probability that no positive case will be found in
the tumour groups smaller than 30 samples, just through
random sampling error, is larger than 0.05. Some tumours
have been examined with a too limited number of samples
(<30) in this study therefore to draw statistically significant
conclusions. Moreover of course, we cannot exclude the pos-
sibility that RET is activated in non-thyroid neoplasias that
have not been analysed at all in this study. It is also possible
that mechanisms other than the gene rearrangement des-
cribed in thyroid tumours, for example point mutations,
could activate RET in non-thyroid neoplasms, but it is
worthwhile to mention that all the activated versions of RET
described to date which occurred either in vivo or in vitro
were due to gene rearrangement (see above). Finally a limita-
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Figure 3 Representative results of RT-PCR followed by Southern blotting. The primers shown in Table I were used for amplifying
a fragment of the RET/PTC cDNA. For evaluating the quality of each RNA a part of c-raf-1 gene was amplified. TPC-1 (lane 15)
was used as a positive control. (a) RT-PCR on breast carcinomas. (b) RT-PCR on hepatocellular carcinomas.
is able to detect only the fusion of RET to H4 and recently
cases in which the activation of RET, in thyroid tumours,
were caused by fusion to genes different from H4 have been
reported, however these cases seem to represent less than
30% of all the RET-positive cases (Bongarzone et al., 1993).
In conclusion these results suggest that RET activation is a
molecular event linked only to thyroid neoplasias. Two
hypotheses can be envisaged to explain this finding: the RET
activation may occur only in thyroid cells, or this event
might also occur in other cells, but it is unable to drive cells
of non-thyroid origin to the neoplastic phenotype. The
generation of transgenic mice carrying an activated RET
oncogene, under the transcriptional control of the
metallothioneine-promoter or the MMTV long terminal
repeat, demonstrated induction of melanocytic tumours,
mammary gland adenocarcinomas and other non-thyroid
tumours (Iwamoto et al., 1990; Iwamoto et al., 1991). Thus
the first hypothesis seems more likely. The restriction of the
activation of RET to the thyroid suggests that this oncogene
could act on a specific pathway in thyroid cells. Thus it will
be extremely useful to study the biological activity of the
RET/PTC products in two established differentiated rat
thyroid cell lines that are available in our laboratory
(Ambesi-Impiombato et al., 1980; Fusco et al., 1987b).
Recently we have demonstrated that the introduction of
RET/PTC is able to block the expression of the thyroid
differentiated functions in the PC CL 3 rat thyroid cell line
(Santoro et al., 1993). We hope that the analysis of this cell
line will be helpful to elucidate the pathway of action of the
RET oncogene into the thyroid cell system.
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